Verrotti Alberto, Cerminara Caterina, Coppola Giangennaro, Franzoni Emilio, Parisi Pasquale, Iannetti Paola, Aloisi Paolo, Tozzi Elisabetta, Cusmai Raffaella, Vigevano Federico, Chiarelli Francesco, Curatolo Paolo
Department of Paediatrics, University of Chieti, Rome, Italy.
Dev Med Child Neurol. 2008 Jan;50(1):29-32. doi: 10.1111/j.1469-8749.2007.02009.x.
The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in juvenile myoclonic epilepsy (JME). The study group consisted of 32 patients with epilepsy (20 males, 12 females) with a mean age of 13 years 3 months (SD 7y 11mo) at seizure onset. LEV was administered as the first drug; all patients were followed up at 6 and 12 months. The dose that achieved seizure control ranged from 1000 to 2500mg/daily. At 6-month evaluation: 15 patients were seizure free; 14 patients were responders (>50% reduction in seizures); and three patients had marginal effects (<50% reduction of seizures). At 12-month evaluation: 29 patients were seizure free; three patients were responders. No patients reported adverse events. These data provide preliminary evidence that LEV may be effective for treating patients with newly diagnosed JME.
本研究的目的是评估左乙拉西坦（LEV）单药治疗青少年肌阵挛性癫痫（JME）的疗效和耐受性。研究组由32例癫痫患者组成（20例男性，12例女性），癫痫发作起始时的平均年龄为13岁3个月（标准差7岁11个月）。LEV作为首选用药；所有患者在6个月和12个月时进行随访。实现癫痫控制的剂量范围为每日1000至2500mg。在6个月评估时：15例患者无癫痫发作；14例患者有反应（癫痫发作减少>50%）；3例患者有边缘效应（癫痫发作减少<50%）。在12个月评估时：29例患者无癫痫发作；3例患者有反应。没有患者报告不良事件。这些数据提供了初步证据，表明LEV可能对新诊断的JME患者有效。
